A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.

NCT Number	NCT06504589
Lead Sponsor	Nicole Hamblett Collaborators: Washington University School of Medicine, Florida State University, University of North Carolina, Chapel Hill, University of Toronto, Cystic Fibrosis Foundation
Conditions	Cystic Fibrosis
Enrollment	400 participants
Start Date	2024-09-18
Primary Completion	2029-08-14 (estimated)
Study Completion	2029-08-14 (estimated)
Updated on ClinicalTrials.gov	2025-10-01